Europe proposes nanotech med tech guidelines; Intersect ENT prices IPO;

@FierceMedDev: Nanoparticles point to cancerous tumors in MRIs. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: Sofinnova closes $500M venture fund, keeps late-stage focus. Article | Follow @StacyALawrence

@VarunSaxena2: Frieden: "What works for Ebola is old fashioned public health." Says developing vaccine is difficult. | Follow @VarunSaxena2

@MichaelGFierce: Most absorbent material on Earth gives poorly soluble drugs a boost. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: The top 5 vaccine makers brought in 86% of all vaccine sales in 2013. Find out who made the list here. Feature | Follow @EmilyWFierce

> Preliminary guidelines on the use of nanomaterials in medical devices was released by the European Commission. They are accepting public comments on their guideline draft through the beginning of October. Guidelines

> Recently deceased computer hacker Barnaby Jack used his skills to show Medtronic ($MDT) and other companies the flaws in their security. Story

> Sinus device maker Intersect ENT priced a $55 million IPO; the per share price was $11, at the low end of its proposed range. More

> A CPR-assisting medical device has joined the market, thanks to a product launch from Emergency Medical Products after an FDA approval. Release

Biotech News

@FierceBiotech: We're looking for 2014's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: Purdue earns a nod--and a quick slap--for abuse-resistant painkiller. News | Follow @JohnCFierce

@DamianFierce: $GILD's idelalisib will carry a boxed warning over serious liver toxicities. Here's the FDA's announcement. Release | Follow @DamianFierce

@EmilyMFierce: GlaxoSmithKline steps closer to making world's first malaria vaccine. More from The Telegraph | Follow @EmilyMFierce

> FDA opens the door for a Novartis biosimilar of Amgen's Neupogen. Report

> A new VC player debuts with global plans to invest $150M in biotech startups. Article

> Israel's Atox banks $23M to fight flesh-eating bacteria. Story

Pharma News

@FiercePharma: Top-read in FP Weds: News flash for biopharma bosses: More than half your employees want to leave. Story | Follow @FiercePharma

@TracyStaton: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. More | Follow @TracyStaton

@EricPFierce: 3-D manufacturing being used in medical devices. When will pharma benefit? FierceMedicalDevices feature | Follow @EricPFierce

@CarlyHFierce: GlaxoSmithKline's the No. 3 vaccines maker now, but its Novartis assets may change that picture. More | Follow @CarlyHFierce

> BMJ targets Pradaxa safety, scolding Boehringer, FDA and EMA alike. Story

> Eli Lilly's Q2 profit sags on patent expirations but beats (low) expectations. Article

> Can Gilead break into cancer? With Zydelig approval, it gets its chance. More

Vaccines News

> Aduro nabs FDA 'breakthrough' nod for pancreatic cancer vaccine combo. More

> SEC charges CytoGenix CEO, 'serial con artist' with fraud. News

> Sinovac nabs Chinese vaccine tenders for hep A, influenza. Item

> GSK submits world's first malaria vaccine for EMA approval. Story

> Fluviral, FluLaval Tetra production on hold at Glaxo's troubled Quebec plant. Article

Pharma Manufacturing News

> Out with the new and in with the old after GSK trips up at vaccine plant. Story

> AmerisourceBergen deal with Walgreen reaps rewards, and costs. More

> FDA warns hospitals that Texas compounder's products are unsafe. Article

> Indian API maker voluntarily halts shipments to the U.S. Story

> Feds extract guilty plea from Turkish man accused of smuggling counterfeit Avastin. Report

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.